Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure

What Was Tested

The paper reports a study of Teduglutide (GLP-2 analog), published as a randomized controlled trial.

Although home parenteral nutrition (PN) can save the lives of patients with massive bowel loss that results in short-bowel syndrome and intestinal failure, quality of life is impaired by PN and its complications.

Who Took Part

The study group was 52 patients.

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized and double-blind.

Random assignment meant chance, not the researchers, decided who got Teduglutide (GLP-2 analog) and who got the comparison, which limits bias.

As a double-blind Teduglutide (GLP-2 analog) study, the assignments were hidden from both participants and investigators until the end.

A time span of 24 weeks appears in the methods.

What Was Measured

PubMed files the paper under topics including Gastrointestinal Agents, Parenteral Nutrition, Peptides and Short Bowel Syndrome.

What This Means in Plain Language

The paper is a randomized and double-blind study of Teduglutide (GLP-2 analog) in 52 patients over 24 weeks.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association), a journal based in United States.

More context: the Teduglutide (GLP-2 analog) compound page.